Drug intelligence / Profile preview

Nanovac

Development stage: Unknown
Lead developer: Intravacc
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

Nanovac is an intranasal nanoparticulate vaccine platform based on soluble nano-spheres containing synthetic mini-proteins designed to induce mucosal and systemic immunity against SARS-CoV-2 and related betacoronaviruses. Developed by Intravacc in collaboration with Leiden University Medical Center, the formulation delivers engineered coronavirus antigens to the upper respiratory tract via nasal spray, aiming to elicit broad neutralizing antibody and T cell responses that block infection at the portal of entry and provide cross-protection against COVID-19, SARS-1, MERS, and other betacoronaviruses.[6]

Beyond the preview

Go deeper on Nanovac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanovac.

Explore the full profile